NATiV3
Don't let NASH be your silent partner.
The NATiV3 Study is now enrolling.
NASH (non-alcoholic steatohepatitis) is the result of fat buildup and inflammation in the liver, which can cause serious health hazards. If you have been diagnosed with NASH or liver fibrosis, you may be eligible to participate in a clinical study evaluating an investigational treatment.
To see if the NATiV3 Study is right for you, please contact us.
Location: MNGI Digestive Health, Northeast Minneapolis Clinic
Physician Investigator: Dr. Hanouneh
Study Coordinator: Naomi Mugarura
MONARCH
The MONARCH Study is now enrolling.
MAFLD (metabolic dysfunction - associated fatty liver disease) defines a range of conditions characterized by an increased amount of fat in the liver. MAFLD can develop into metabolic dysfunction - associated steatohepatitis (MASH), which is characterized by inflammation and fibrosis. If you have been diagnosed with MAFLD, MASH or liver fibrosis you may be eligible to participate in a clinical study evaluating an investigational treatment.
To see if the MONARCH Study is right for you, please contact us below.
Location: MNGI Digestive Health, Northeast Minneapolis Clinic
Physician Investigator: Dr. Hanouneh
Study Coordinator: Naomi Mugarura